Rebif

Ocrevus Outperforms Rebif in Preventing Myelin Loss in Trial

Two years of treatment with Ocrevus (ocrelizumab) outperformed Rebif (interferon beta-1a) at preventing myelin loss in people with relapsing multiple sclerosis (MS), according to a new analysis of data from the OPERA II clinical trial. Ocrevus’ protection against demyelination was observed both in MS lesions,…

High Adherence to Rebif Seen With RebiSmart Use, Chats With Doctor

Regular feedback from doctors about dosing data and health status is associated with high and sustained treatment adherence to RebifĀ (interferon beta-1a) amongĀ multiple sclerosis (MS)Ā patients using the RebiSmart autoinjector, a two-year observational study shows. This study’s level of treatment adherence ā€” 97.9% ā€” was comparable or superior to the…

Headache a Common Side Effect of Interferon-beta Treatment, Study Finds

New or worsening headaches are a more common side effect of interferon-beta (IFN-beta) treatment in people with multiple sclerosisĀ (MS) than previously appreciated, a new study suggests. The study, “Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization,” was published in theĀ Journal of Pain Research.

New Study Supports Hitting MS Fast and Hard

The question of how quickly to start a disease-modifying therapy (DMT) after a multiple sclerosis (MS) diagnosis is one that I frequently see when I browse online. It goes hand in hand with questions about which DMT is best to start with. There are many things to consider when…

Patients with Stable Disease Who Switch to Another Interferon Therapy at Greater Risk of Flares, Study Reports

Multiple sclerosis (MS) patients who have been relapse-free while using an interferon-beta (IFN-Ī²) therapy but switch to anotherĀ IFN-Ī² are significantly more like to start experiencingĀ flaresĀ than patients who remain on their initial interferon treatment, a real-world study reports. Its results support letting patients remain on a current IFN-Ī² medication…

DMTs Are Cost-Effective and Help to Slow MS Progression, 10-Year Study from UK Reports

Four disease-modifying therapies (DMTs) for Ā multiple sclerosisĀ ā€”Ā Avonex, Rebif, Betaferon, and CopaxoneĀ ā€” are cost-effective and reduce disease progression in MS patients, especially those with relapsing-remitting disease, according to 10-year, real-world results from U.K.ā€™s MS Risk Sharing Scheme (RSS). But the long-term benefits observed wane over…

#EAN2018 ā€“ Ocrevus Lowers Relapse Rates Over Long Term and Better Than Rebif Does, Data Show

Long-term treatment with Ocrevus (ocrelizumab) Ā ā€” as well as switching from Rebif (interferon beta-1a) to Ocrevus ā€” leads to a significant and sustained reduction in disease activity in relapsing forms of multiple sclerosis (MS). TheseĀ previouslyĀ reportedĀ findingsĀ are further supported by the latest results drawn from pooled data…

#CMSC2018 – Gains in Functional Abilities Seen in Lemtrada-treated MS Patients Over Six Years, CARE-MS II Extension Study Shows

Patients with active relapsing-remitting multiple sclerosis (MS) continue to show improvement ā€” lesser functional disability across a variety of measures ā€” and often without the need for continuous treatment after takingĀ LemtradaĀ for two years, according to six-year results from the CARE-MS II extension study. These results were shared in a…

#AAN2018 – Switching from Rebif to Ocrevus Improves MS, Extension Study Shows

Continuous treatment with Ocrevus (ocrelizumab) or switching from Rebif (interferon beta-1a)Ā to Ocrevus leads to aĀ significant long-term reduction in relapsing multiple sclerosis activity, a two-year extension study shows. Ocrevus’s maker, Genentech,Ā drew the results from anĀ open-label extension of the Phase 3 OPERA trials. Researchers will present the findings at…

What’s Hot and What’s Not Among MS Therapies?

The newest kids on the MS block, disease-modifying therapies (DMT) such as Genentech’s Ocrevus (ocrelizumab) and Sanofi Genzyme’s Lemtrada (alemtuzumab), are attracting a lot of interest these days. But, some DMTs that have been around for more than two decades are still being prescribed by a lot of neurologists.

New Ocrevus Data, Post-FDA Approval, Supports Range of Benefits, Genentech’s Hideki Garren Says

OcrevusĀ (ocrelizumab), Genentechā€™sĀ humanized anti-CD20 monoclonal antibody, continues to show clear evidence that it helps to slow disease progression and enable better function ā€” including in the hands and limbs ā€” ofĀ relapsing multiple sclerosis (MS)Ā and primary progressive multiple sclerosis (PPMS), latest data reveals. TheĀ first FDA-approved therapy ā€” in March…